Can-Fite BioPharma Ltd. ADR is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule therapies for cancer, liver diseases, inflammatory conditions, and erectile dysfunction. The company’s current pipeline centers on drug candidates designed to modulate the A3 adenosine receptor, a biological target associated with inflammatory and cancer-related pathways. Its product portfolio includes programs such as Piclidenoson, Namodenoson, and CF602, reflecting a research model built around targeted treatments for serious unmet medical needs. Can-Fite BioPharma also works on cannabinoid-based programs and biomarker tools that support patient selection and therapeutic development. Headquartered in Israel, the company operates as a specialist drug developer within the global biotechnology sector, where it plays a role in advancing precision-oriented therapies from clinical research toward potential medical use.
Website26 Ben Gurion Street
Ramat Gan, 5257346
Israel
Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the publication of a peer-reviewed case report
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for H1 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and d
RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise
Investors talking about CANF also mention
What share of all stock conversation is about CANF?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% +0 | 0% +0 |
Of the messages about CANF that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 30.65% -69.35 | 69.98% -6.22 | ||
| Bearish | — | — | 69.35% +69.35 | 30.02% +6.22 |
Of the messages about CANF that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 62.5% | 29.74% | ||
| Technical Analysis | — | — | 37.5% | 9.72% | ||
| Analysts | — | — | 0% | 31.88% | ||
| Controversies | — | — | 0% | 0% | ||
| Earnings | — | — | 0% | 0% | ||
| Macro | — | — | 0% | 28.66% |
Of the messages about CANF, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | 34.68% | 28.41% | ||
| Newcomers | — | — | 65.32% | 71.59% |